| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-106 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于雪榕转债即将停止交易暨赎回实施的重要提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025 年 10 月 9 日 2025 年 10 月 9 日为"雪榕转债"最后一个交易日，当日"雪榕转债"简称 为"Z 榕转债"；2025 年 10 月 9 日收市后，"雪榕转债"将停止交易。 2、最后转股日：2025 年 10 月 14 日 2025 年 10 月 14 日为"雪榕转债"最后一个转股日，当日收市前，持有"雪 榕转债"的投资者仍可进行转股；2025 年 10 月 14 日收市后，仍未转股的"雪 榕转债"，将按照 100.93 元/张的价格强制赎回，因目前"雪榕转债"二级市场 价格与赎回价格存在很大差异，特别提醒"雪榕转债"持有人注意在限期内转股， 如果投资者未及时转股，可能面临损失，敬请投资者注意投 ...

上海雪榕生物科技股份有限公司 关于雪榕转债即将停止交易暨赎回实施的重要提示性公告 | 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-105 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025 年 10 月 9 日 2025 年 10 月 9 日为"雪榕转债"最后一个交易日，当日"雪榕转债"简称 为"Z 榕转债"；2025 年 10 月 9 日收市后，"雪榕转债"将停止交易。 2、最后转股日：2025 年 10 月 14 日 2025 年 10 月 14 日为"雪榕转债"最后一个转股日，当日收市前，持有"雪 榕转债"的投资者仍可进行转股；2025 年 10 月 14 日收市后，仍未转股的"雪 榕转债"，将按照 100.93 元/张的价格强制赎回，因目前"雪榕转债"二级市场 价格与赎回价格存在很大差异，特别提醒"雪榕转债"持有人注意在限期内转股， 如果投资者未及时转股，可能面临损失，敬请投资者注意投 ...

Core Viewpoint - Xuerong Biological announced a mandatory redemption of its convertible bonds at a price of 100.93 yuan per bond if they are not converted by October 14, 2025, highlighting a significant disparity between the market price and the redemption price, which may lead to substantial investment losses for bondholders [1] Summary by Relevant Sections - **Company Announcement** - Xuerong Biological has issued a notice regarding the mandatory redemption of its convertible bonds, referred to as "Xuerong Convertible Bonds" [1] - The redemption will occur if the bonds are not converted by the specified date, October 14, 2025 [1] - **Market Implications** - There is a notable difference between the current secondary market price of the bonds and the redemption price, which could result in large investment losses for holders if the bonds are forced to be redeemed [1] - The company has specifically warned bondholders to consider converting their bonds before the deadline to avoid potential losses [1]

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-104 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于雪榕转债即将停止交易暨赎回实施的重要提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、最后交易日：2025 年 10 月 9 日 2025 年 10 月 9 日为"雪榕转债"最后一个交易日，当日"雪榕转债"简称 为"Z 榕转债"；2025 年 10 月 9 日收市后，"雪榕转债"将停止交易。 2、最后转股日：2025 年 10 月 14 日 2025 年 10 月 14 日为"雪榕转债"最后一个转股日，当日收市前，持有"雪 榕转债"的投资者仍可进行转股；2025 年 10 月 14 日收市后，仍未转股的"雪 榕转债"，将按照 100.93 元/张的价格强制赎回，因目前"雪榕转债"二级市场 价格与赎回价格存在很大差异，特别提醒"雪榕转债"持有人注意在限期内转股， 如果投资者未及时转股，可能面临损失，敬请投资者注意投 ...

Company Overview - Shanghai Xuerong Biotechnology Co., Ltd. is located at 1487 Huifeng West Road, Fengxian District, Shanghai, established on December 8, 1997, and listed on May 4, 2016 [1] - The company's main business involves the research and development, cultivation, and sales of edible mushrooms, with revenue composition as follows: Enoki mushrooms 73.31%, King oyster mushrooms 22.27%, others 1.65%, supplementary 1.58%, and culture medium 1.19% [1] Stock Performance - On September 25, Xuerong Biotechnology's stock rose by 2.18%, reaching 6.08 CNY per share, with a trading volume of 84.26 million CNY and a turnover rate of 2.75%, resulting in a total market capitalization of 3.634 billion CNY [1] - Year-to-date, the stock price has increased by 75.22%, with a 3.93% rise over the last five trading days, a 3.65% decline over the last 20 days, and an 8.02% decline over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on May 20, where it recorded a net purchase of 57.18 million CNY [1] Financial Performance - For the first half of 2025, Xuerong Biotechnology reported operating revenue of 791 million CNY, a year-on-year decrease of 26.17%, and a net profit attributable to the parent company of -103 million CNY, a year-on-year increase of 28.58% [2] - The company has distributed a total of 236 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Shareholder Information - As of June 30, the number of shareholders for Xuerong Biotechnology was 30,200, a decrease of 14.57% from the previous period, while the average circulating shares per person increased by 28.64% to 17,119 shares [2] Industry Classification - Xuerong Biotechnology belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically in the planting industry focused on edible mushrooms [2] - The company is associated with several concept sectors, including NMN concept, small-cap, low-price, biopharmaceuticals, and rural revitalization [2]

Core Viewpoint - Xuerong Biological announced that the "Xuerong Convertible Bonds" will be forcibly redeemed if not converted by the close of trading on October 14, 2025, leading to their delisting from the Shenzhen Stock Exchange [1]. Summary by Relevant Sections - **Redemption Announcement** - The company has set a deadline for the conversion of "Xuerong Convertible Bonds" to avoid forced redemption [1]. - **Investor Advisory** - Bondholders are advised to convert their bonds before the deadline to prevent forced redemption, especially if their bonds are pledged or frozen [1].

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2025-103 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 上海雪榕生物科技股份有限公司 关于提前赎回雪榕转债的第十五次提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"雪榕转债"赎回价格：100.93 元/张（含当期应计利息，当期年利率为 3.00%，且当期利息含税），扣税后的赎回价格以中国证券登记结算有限责任公 司深圳分公司（以下简称"中国结算"）核准的价格为准。 2、赎回条件满足日：2025 年 9 月 3 日 8、投资者赎回款到账日：2025 年 10 月 22 日 9、赎回类别：全部赎回 10、最后一个交易日（2025 年 10 月 9 日）可转债简称：Z 榕转债 11、根据安排，截至 2025 年 10 月 14 日收市后仍未转股的"雪榕转债"将 被强制赎回，本次赎回完成后，"雪榕转债"将在深圳证券交易所（以下简称"深 交所"）摘牌。特提醒"雪榕转债"持有人注意在限期内转股。债券持有人持有 的" ...

Core Viewpoint - Xuerong Bio announced that the "Xuerong Convertible Bonds" will be forcibly redeemed at a price of 100.93 yuan per bond if not converted by October 14, 2025, highlighting a significant disparity between the market price and the redemption price, which may lead to substantial investment losses for bondholders [2] Summary by Relevant Sections - **Company Announcement** - Xuerong Bio has issued a notice regarding the forced redemption of its convertible bonds if they remain unconverted by the specified date [2] - **Market Implications** - The current secondary market price of the "Xuerong Convertible Bonds" is significantly lower than the redemption price, indicating potential financial risks for investors [2] - **Investor Advisory** - The company has specifically warned bondholders to pay attention to the conversion deadline to avoid large investment losses [2]

Group 1 - The company announced the signing of a "Maximum Financing Contract" with Shanghai Rural Commercial Bank on March 2025, indicating a strategic financial partnership [1] - To ensure the fulfillment of the financing contract, the company has signed a "Maximum Mortgage Contract," providing land and property as collateral for the credit facility [1] - The company plans to apply for a comprehensive credit limit of up to 40 million yuan after the expiration of the current credit facility, with the final credit limit and terms subject to bank approval [1] Group 2 - The mortgage guarantee is classified as a self-provided collateral, which falls within the board's review authority and does not require shareholder meeting approval [1]

Group 1 - The company, Xuerong Biotechnology, held its 33rd meeting of the 5th Board of Directors on September 23, 2025, in Shanghai [1] - The meeting reviewed a proposal regarding the company's application for comprehensive credit from banks and the continuation of providing collateral guarantees [1] Group 2 - The industry is currently facing heightened scrutiny regarding bidding processes, particularly in large-scale national procurement, leading to increased requirements for bidders to justify their pricing [1]